Hologic Short Interest Drops 14.5% in March

Medical technology company sees decline in shares shorted amid mixed analyst ratings

Apr. 2, 2026 at 9:54am

Got story updates? Submit your updates here. ›

Hologic, Inc. (NASDAQ:HOLX), a global medical technology company specializing in women's health, saw a 14.5% drop in short interest during March, with the number of shares shorted declining from 8.3 million to 7.1 million. This comes as the company received mixed analyst ratings, with some firms downgrading the stock to 'hold' while others maintained a 'buy' recommendation.

Why it matters

The decline in short interest suggests investors may be growing more bullish on Hologic's prospects, even as the company faces a mixed outlook from analysts. Short interest can be an indicator of market sentiment, and a drop in shares shorted could signal increased confidence in the company's performance.

The details

Hologic's short interest fell from 8,301,510 shares on February 26th to 7,100,246 shares as of March 13th, a 14.5% decrease. This came as the average daily trading volume was 2,957,823 shares, resulting in a days-to-cover ratio of 2.4. Approximately 3.2% of Hologic's shares are currently sold short.

  • As of March 13th, 2026, Hologic's short interest totaled 7,100,246 shares.
  • On February 26th, 2026, Hologic's short interest was 8,301,510 shares.

The players

Hologic, Inc.

A global medical technology company specializing in women's health, headquartered in Marlborough, Massachusetts. Hologic develops and manufactures diagnostic products, imaging systems and surgical solutions.

Weiss Ratings

A research firm that reissued a 'hold (c)' rating on Hologic shares.

Evercore

An investment bank that cut its rating on Hologic from 'outperform' to 'in-line' and lowered the price target from $79 to $78.

Argus

A research firm that downgraded Hologic from a 'buy' rating to a 'hold' rating.

Got photos? Submit your photos here. ›

The takeaway

The drop in Hologic's short interest suggests investors may be growing more optimistic about the company's prospects, even as it faces a mixed outlook from analysts. The decline in shares shorted could signal increased confidence in Hologic's performance, though the company will need to navigate the varying analyst ratings and market sentiment.